Headlines about IRIDEX (NASDAQ:IRIX) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IRIDEX earned a news impact score of 0.13 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 47.0632443713322 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of IRIDEX remained flat at $$6.64 during midday trading on Friday, MarketBeat.com reports. 28,322 shares of the company were exchanged, compared to its average volume of 12,377. The stock has a market cap of $77.27 million, a P/E ratio of -5.98 and a beta of 1.42. IRIDEX has a 52 week low of $4.28 and a 52 week high of $10.98.
IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings results on Thursday, May 3rd. The medical equipment provider reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.02. The company had revenue of $9.51 million for the quarter, compared to the consensus estimate of $8.80 million. IRIDEX had a negative net margin of 35.95% and a negative return on equity of 44.78%. analysts anticipate that IRIDEX will post -1.16 EPS for the current fiscal year.
Separately, Zacks Investment Research downgraded shares of IRIDEX from a “hold” rating to a “sell” rating in a report on Thursday, March 1st.
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.